Skip to main content

Table 2 Antibody model parameters

From: Modelling population-level impact to inform target product profiles for childhood malaria vaccines

Scenario

tdose 4 (months)

ABdose 4 (EU/mL)

V max

α

β

A: RTS,S/AS01 phase 3

18

277

0.93

0.74

99.2

B: Intermediate

13

450

0.93

0.85

85.0

C: Modified

8

621

0.93

0.95

70.0

  1. These parameters correspond to three vaccine scenarios: an RTS,S/AS01 phase 3 efficacy profile (A), a modified profile based on the phase 2a challenge study (C) [6, 7] and an intermediate profile (B). The antibody titre and efficacy profiles are provided in Additional file 1: Figure S6 and Fig. 4, respectively. The parameter ABdose 4 represents the antibody titre following the fourth vaccine dose at time tdose 4
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us